Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)
China · Delayed Price · Currency is CNY 30.40
+0.56 (1.88%)
Aug 4, 2026, 3:00 PM CST
SHA:603590 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,701 | 6,321 | 3,724 | 5,959 | 3,903 | 5,084 | |
Market Cap Growth | -53.46% | 69.72% | -37.51% | 52.69% | -23.24% | -12.98% |
Enterprise Value | 4,531 | 5,970 | 3,614 | 5,764 | 3,593 | 4,468 |
Last Close Price | 29.84 | 39.32 | 22.82 | 36.50 | 23.76 | 30.62 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 28.16 | 38.08 | 88.21 | 39.61 | 38.46 | 34.36 |
Forward PE | 26.41 | 37.32 | 17.89 | 34.78 | - | - |
PS Ratio | 5.12 | 6.91 | 4.51 | 6.48 | 4.50 | 6.28 |
PB Ratio | 1.34 | 1.81 | 1.09 | 1.77 | 1.22 | 1.62 |
P/TBV Ratio | 1.97 | 2.66 | 1.62 | 2.83 | 1.94 | 2.57 |
P/FCF Ratio | 36.75 | 101.57 | 54.59 | 60.54 | 166.94 | - |
P/OCF Ratio | 28.02 | 54.64 | 21.62 | 29.89 | 32.61 | 90.44 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.94 | 6.52 | 4.38 | 6.27 | 4.15 | 5.52 |
EV/EBITDA Ratio | 20.67 | 28.07 | 24.09 | 34.86 | 23.71 | 30.97 |
EV/EBIT Ratio | 24.20 | 32.59 | 30.43 | 44.49 | 30.07 | 39.71 |
EV/FCF Ratio | 35.42 | 95.94 | 52.97 | 58.55 | 153.69 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.09 | 0.09 | 0.06 | 0.05 | 0.00 | 0.01 |
Debt / EBITDA Ratio | 1.51 | 1.49 | 1.35 | 0.87 | 0.08 | 0.13 |
Debt / FCF Ratio | 2.59 | 5.15 | 3.07 | 1.52 | 0.53 | - |
Net Debt / Equity Ratio | -0.13 | -0.19 | -0.14 | -0.20 | -0.19 | -0.19 |
Net Debt / EBITDA Ratio | -2.11 | -3.05 | -3.23 | -4.00 | -4.05 | -4.16 |
Net Debt / FCF Ratio | -3.57 | -10.43 | -7.11 | -6.71 | -26.26 | 5.54 |
Asset Turnover | 0.23 | 0.23 | 0.21 | 0.26 | 0.26 | 0.23 |
Inventory Turnover | 1.45 | 1.45 | 1.43 | 2.37 | 3.02 | 2.61 |
Quick Ratio | 2.63 | 2.88 | 2.80 | 3.49 | 5.51 | 5.62 |
Current Ratio | 3.05 | 3.04 | 3.08 | 3.80 | 5.90 | 6.12 |
Return on Equity (ROE) | 4.89% | 4.90% | 0.63% | 5.73% | 3.92% | 5.39% |
Return on Assets (ROA) | 2.94% | 2.86% | 1.93% | 2.25% | 2.20% | 1.97% |
Return on Invested Capital (ROIC) | 5.59% | 5.65% | 2.33% | 4.91% | 4.13% | 4.85% |
Return on Capital Employed (ROCE) | 5.10% | 5.00% | 3.30% | 3.70% | 3.70% | 3.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.59% | 2.63% | 1.13% | 2.53% | 2.60% | 2.91% |
FCF Yield | 2.72% | 0.98% | 1.83% | 1.65% | 0.60% | -2.13% |
Dividend Yield | 1.17% | 0.89% | 2.63% | 0.82% | 0.84% | 0.98% |
Payout Ratio | 61.09% | 61.70% | 126.71% | 23.23% | 46.26% | 37.58% |
Buyback Yield / Dilution | -1.07% | -2.06% | 0.23% | -0.37% | 0.82% | 1.26% |
Total Shareholder Return | 0.11% | -1.17% | 2.86% | 0.45% | 1.66% | 2.24% |